Acadia Pharmaceuticals Inc. (ACAD) and Saniona, on Monday announced positive initial results from their Phase 1 multiple-ascending-dose or MAD study of ACP-711 formerly SAN711 in healthy volunteers.
The study, which was completed with no serious adverse events, demonstrated that ACP-711 was safe and well-tolerated across all dosing cohorts.
Most adverse events reported were mild, and there were no concerns regarding cardiovascular, neurological, or safety laboratory findings.
Following the favorable results, the companies are now seeking regulatory approval to extend the study to higher repeated doses and to include elderly healthy volunteers.
The study is currently paused until this approval is obtained. ACP-711 is being prioritized as the lead treatment for essential tremor, a neurological disorder.
The companies believe that ACP-711 has significant potential to address unmet needs in treating essential tremor.
Both Acadia Pharmaceuticals and Saniona continue to focus on advancing treatments for neurological disorders, with ACP-711 as a key part of their collaborative efforts.
Currently, ACAD is trading at $19.44 down by 0.82 percent on the Nasdaq.
For comments and feedback: editorial@rttnews.com